Armistice reports 9.99% stake in Citius Oncology

Citius Oncology, Inc. Schedule 13G/A: Armistice Capital, LLC and Steven Boyd report beneficial ownership of 9,299,917 shares of common stock, representing 9.99% of the class as of 03/31/2026.

Accepted by SEC EDGAR 05/15/2026 - 11:11 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Citius Oncology, Inc. Schedule 13G/A: Armistice Capital, LLC and Steven Boyd report beneficial ownership of 9,299,917 shares of common stock, representing 9.99% of the class as of 03/31/2026. The filing is Amendment No. 3.

The disclosure states Armistice Capital is the investment manager of Armistice Capital Master Fund Ltd., which is the direct holder; Armistice Capital and Mr. Boyd report shared voting and dispositive power over the 9,299,917 shares, while the Master Fund disclaims beneficial ownership by reason of its inability to vote or dispose under the Investment Management Agreement.

Insights

Corporate Governance Analyst

Armistice reports a near-10% stake held through a managed fund with shared voting power.

The filing shows 9,299,917 shares (9.99%) held by Armistice Capital Master Fund Ltd., with Armistice Capital exercising voting and investment authority under an Investment Management Agreement. The Master Fund is identified as the direct holder while disclaiming beneficial ownership due to the agreement.

Key dependencies are the contractual allocation of authority in the Investment Management Agreement and any subsequent amendments; future filings may update percentages or ownership structure if holdings change.

Key Figures

Shares beneficially owned: 9,299,917 shares Percent of class: 9.99% Reporting form: Schedule 13G/A (Amendment No. 3) +2 more

5 metrics

Shares beneficially owned 9,299,917 shares Amount reported as beneficially owned (Item 4)

Percent of class 9.99% Percent of common stock as reported (Item 4)

Reporting form Schedule 13G/A (Amendment No. 3) Form type listed on the filing cover

Reporting period 03/31/2026 Date shown on the filing cover as the reporting date

CUSIP 17331Y109 CUSIP for Citius Oncology common stock shown on the cover

Key Terms

Investment Management Agreement, beneficially own, shared voting power

3 terms

Investment Management Agreement regulatory

"Armistice Capital is the investment manager of Armistice Capital Master Fund Ltd."

An investment management agreement is a written contract that hires a professional to make buying, selling and strategy decisions for an investment account or fund, and sets out their duties, fees, risk limits, performance measures and reporting requirements. It matters to investors because the agreement determines who controls the money, how much the service costs, what risks are allowed, and how success or failure is measured—think of it as the service contract that defines expectations and remedies for a hired portfolio manager.

beneficially own financial

"Armistice Capital exercises voting and investment power ... and thus may be deemed to beneficially own"

Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.

shared voting power financial

"Shared Voting Power 9,299,917.00"

Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does Armistice Capital report in CTOR?

Armistice reports beneficial ownership of 9,299,917 shares, equal to 9.99% of Citius Oncology's common stock as of 03/31/2026. The shares are held directly by the Master Fund.

Who holds voting and investment power over these CTOR shares?

The filing states Armistice Capital exercises shared voting and dispositive power over the 9,299,917 shares pursuant to its Investment Management Agreement with the Master Fund.

Does Steven Boyd personally own the reported CTOR shares?

Steven Boyd is reported as managing member of Armistice Capital and may be deemed to beneficially own the shares through that role; the filing lists shared voting and dispositive power attributed to him via Armistice.

What does the Master Fund's disclaimer mean in this filing?

The Master Fund disclaims beneficial ownership because, per the filing, it lacks the ability to vote or dispose of the securities due to the Investment Management Agreement with Armistice Capital.

When was this Schedule 13G/A signed?

Signatures on the amendment are dated 05/15/2026, and the ownership snapshot in the filing is anchored to 03/31/2026 as shown on the cover.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 3)

Citius Oncology, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

17331Y109

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 17331Y109

1

Names of Reporting Persons

Armistice Capital, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 9,299,917.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 9,299,917.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

9,299,917.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.99 %

12

Type of Reporting Person (See Instructions)

IA, OO

SCHEDULE 13G

CUSIP Number(s): 17331Y109

1

Names of Reporting Persons

Steven Boyd

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 9,299,917.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 9,299,917.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

9,299,917.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.99 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Citius Oncology, Inc.
(b)	Address of issuer's principal executive offices: 11 COMMERCE DRIVE, 1ST FLOOR, CRANFORD, NJ, 07016
Item 2.
(a)	Name of person filing: Armistice Capital, LLC Steven Boyd Collectively, the "Reporting Persons"
(b)	Address or principal business office or, if none, residence: Armistice Capital, LLC 510 Madison Avenue, 7th Floor New York, New York 10022 United States of America Steven Boyd c/o Armistice Capital, LLC 510 Madison Avenue, 7th Floor New York, New York 10022 United States of America
(c)	Citizenship: Armistice Capital, LLC - Delaware; Steven Boyd - United States of America
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 17331Y109
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 9,299,917
(b)	Percent of class: 9.99%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 9,299,917
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 9,299,917 Armistice Capital, LLC ("Armistice Capital") is the investment manager of Armistice Capital Master Fund Ltd. (the "Master Fund"), the direct holder of the Shares, and pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund. Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund. The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. The Master Fund, a Cayman Islands exempted company that is an investment advisory client of Armistice Capital, has the right to receive dividends from, or the proceeds from the sale of, the reported securities.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Armistice Capital, LLC

Signature:	/s/ Steven Boyd
Name/Title:	Steven Boyd - Managing Member
Date:	05/15/2026

Steven Boyd

Signature:	/s/ Steven Boyd
Name/Title:	Steven Boyd
Date:	05/15/2026

Exhibit Information

JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: May 15, 2026 Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd - Managing Member Steven Boyd By: /s/ Steven Boyd